24th week of 2020 patent applcation highlights part 32 |
Patent application number | Title | Published |
20200181565 | Bacterial Growth on Non-Animal Derived Media - The invention is directed to tools, compositions, and methods for the cultivation of microorganisms in culture media that is devoid of animal-derived materials such as blood, and, in particular, to compositions of meat-free media. | 2020-06-11 |
20200181566 | MICROFLUIDIC THREE-DIMENSIONAL CELL CULTURE DEVICE - Described herein are various embodiments directed to microfluidic cell culture devices, systems, and methods. Embodiments of devices and systems disclosed herein may be used to grow and characterize one or more phenotypes of a cell sample. An apparatus may include an apparatus including a substrate defining a cavity, and further include a scaffold disposed within the cavity. The substrate and the scaffold may collectively define a set of channels including a first channel and a second channel. The first channel may be configured to receive and culture a cell sample during use. The second channel may be configured to receive a fluid during use. The scaffold may be configured to permit diffusion of the fluid through the scaffold and into the first channel. | 2020-06-11 |
20200181567 | METHODS OF REPROGRAMMING ANIMAL SOMATIC CELLS - This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease. | 2020-06-11 |
20200181568 | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO GERM CELLS - The invention provides a method for inducing human primordial germ cell-like (PGC-like) cells from human pluripotent stem cells, with high efficiency and high reproducibility, and a cell surface marker for identifying human PGC-like cells. In particular, the invention provides a method for producing a human PGC-like cell from a human pluripotent stem cell, includes a step of producing a mesoderm-like cell by culturing a human pluripotent stem cell in a culture medium comprising activin A and a GSK3β inhibitor, and a step of culturing the mesoderm-like cell in a culture medium containing BMP. The invention also provides a method for producing an isolated human PGC-like cell, which includes the aforementioned two steps and the additional step of selecting a cell positive to at least one cell surface marker selected from the group consisting of PECAM (CD31), INTEGRINa6 (CD49f), INTEGRINβ3 (CD61), KIT (CD117), EpCAM, PODOPLANIN and TRA1-81. | 2020-06-11 |
20200181569 | EXPANDABLE CELL POPULATIONS FROM BRAIN BIOPSIES OF LIVING SUBJECTS - The present invention relates to a method of producing expandable cultured brain cells. The brain cells are neurotrophic factor (NTF) positive. The expandable cultured brain cells are obtained by culturing a biopsy obtained from the cortical and/or subcortical brain region of a living subject. The biopsies can be obtained during neurosurgical procedures such as deep brain stimulation. The expandable cultured brain cells of the present invention are useful for the treatment of neurological diseases and other medical conditions. | 2020-06-11 |
20200181570 | ELECTROACTIVE POLYMERIC SCAFFOLDS AND METHOD FOR DELIVERING NERVE GROWTH FACTOR TO NERVE TISSUE - A polymerizable unit that yields an electrochemically responsive polymer (advantageously pyrrole) is anchored by polymerization within a polycaprolactone matrix to form an electroactive scaffold upon which cells can be cultured and in which the micro- and nano-topological features of the polycaprolactone matrix are preserved. A scaffold manufactured in accordance with the preferred embodiment can support Schwann cells, which produce nerve growth factor when electrically stimulated. Nerve growth factor has been demonstrated to promote the regeneration of nerve tissue. By implanting the scaffold on which Schwann cells have been cultured into damaged nerve tissue and applying a voltage across the scaffold, nerve growth factor is produced, thereby promoting repair of the damaged nerve tissue. | 2020-06-11 |
20200181571 | USE OF GERM CELLS FOR PREPARING A MICRO HAIR FOLLICLE - The invention relates to the use of germ cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity. | 2020-06-11 |
20200181572 | Methods and Kits for Cell Activation - Provided herein are methods of activating immune cells. The method includes providing a population of immune cells and contacting the population of immune cells with a first agent and a second agent. The first agent includes an immune cell activator attached to a first binder moiety, and the second agent includes at least one capture oligomer. The at least one capture oligomer is capable of associating with the first binder moiety. Also provided are kits for activating immune cells. | 2020-06-11 |
20200181573 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES - Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided. | 2020-06-11 |
20200181574 | IDENTIFICATION OF T-CELL TRAFFICKING GENES AND USES THEREOF FOR INCREASING INFILTRATION OF T-CELLS INTO SOLID TUMORS - Disclosed are compositions, kits, and methods for identifying genes that are involved in T-cell trafficking. In particular, the compositions, kits, and methods may be used to identify genes involved in T-cell trafficking and/or infiltration into tumors such as genes that encode immune checkpoint regulators and/or stimulatory agents. The disclosed compositions, kits, and methods utilize the Sleeping Beauty transposon system in a mouse tumor model to identify genes that are involved in T-cell trafficking and infiltration into tumors. The genes identified in the disclosed methods may provide immunotherapy targets in the tumor microenvironment. The identified genes may be utilized in order to develop therapies that enhance T-cell trafficking and infiltration into tumors and/or T-cell killing of tumors such as in chimeric antigen receptor (CAR) T cell therapies. | 2020-06-11 |
20200181575 | METHODS FOR PRODUCING GENETICALLY ENGINEERED CELL COMPOSITIONS AND RELATED COMPOSITIONS - Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naive-like CD4+ T cells to naive-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods. | 2020-06-11 |
20200181576 | THE USE OF MECHANICAL (ACOUSTIC/SUBSONIC) VIBRATION FOR A NOVEL PARADIGM IN REGENERATIVE MEDICINE AND HUMAN WELL BEING - Methods of acquiring cellular and tissue vibrational patterning to identify signatures capable to induce pluripotency and commitment towards defined lineages, as well as survival under hostile conditions (i.e. oxidative stress) in both human adult stem cells and human adult somatic cells are described. Specifically, the invention relates to the delivery of such signatures to human adult stem cells or human adult somatic cells to induce specific differentiation processes and promote survival to hostile environmental conditions. Further methods are described of targeting tissue resident in vivo to retrieve their ability to sustain self-healing process, therefore affording a Regenerative Medicine executed without the needs for (stem) cell or tissue transplantation. | 2020-06-11 |
20200181577 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG - The present disclosure relates generally to recombinant cardiomyocytes and cardiomyocyte cell lines overexpressing hERG and uses thereof. | 2020-06-11 |
20200181578 | MITOCHONDRIAL TRANSPLANTATION TO ALTER ENERGY METABOLISM - A method of altering energy metabolism in a recipient cell including: identifying the recipient cell as being in need of altering its oxidative phosphorylation status, obtaining exogenous mitochondria, and introducing into the recipient cell the exogenously obtained mitochondria, wherein the exogenously obtained mitochondria functions in the recipient cell to increase or decrease oxidative phosphorylation and/or glycolysis. Also disclosed are isolated cells that include an exogenous mitochondria, wherein the cell demonstrates increased energy metabolism compared to a control cell of the same type but wherein the control cell lacks exogenously added mitochondria. Also disclosed are methods of treating a subject suffering from ischemia or a mitochondrial dysfunction including administering one or more group of isolated cells including exogenous mitochondria as disclosed herein to the subject, wherein the one or more isolated cell including exogenous mitochondria improve symptoms of the ischemia or the mitochondrial dysfunction. | 2020-06-11 |
20200181579 | PRODUCTION METHOD FOR KIDNEY-LIKE TISSUE - A novel tissue usable for a kidney tissue model is provided. A method for producing a kidney-like tissue includes co-culturing a cell group containing mesenchymal stem cells, vascular endothelial cells, and clonal embryonic kidney cells. | 2020-06-11 |
20200181580 | Engineered Liver Tissues, Arrays Thereof, and Methods of Making the Same - Engineered, living, three-dimensional liver tissue constructs comprising: one or more layers, wherein each layer contains one or more liver cell types, the one or more layers cohered to form a living, three-dimensional liver tissue construct. In some embodiments, the constructs are characterized by having at least one of: at least one layer comprising a plurality of cell types, the cell types spatially arranged relative to each other to create a planar geometry; and a plurality of layers, at least one layer compositionally or architecturally distinct from at least one other layer to create a laminar geometry. Also disclosed are arrays and methods of making the same. Also disclosed are engineered, living, three-dimensional liver tissue constructs for use in the augmentation or restoration of one or more liver functions, by in vivo delivery of tissue or utilization of tissue in an extracorporeal device. | 2020-06-11 |
20200181581 | COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA - The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy. | 2020-06-11 |
20200181582 | NOVEL IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING LYMPHOCYTES DERIVED FROM VECTOR TRANSDUCED HSCS FOR THERAPY OF DISORDERS - The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders. | 2020-06-11 |
20200181583 | NADPH Oxidase Proteins - The present invention relates to novel NADPH oxidase proteins, or Nox, the use thereof, the method of preparation thereof and the method for identification thereof. | 2020-06-11 |
20200181584 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY - The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5′ UTR derived from a gene expressed by | 2020-06-11 |
20200181585 | Mutant of Cyclodextrin Glycosyltransferase - The present invention discloses a mutant of cyclodextrin glycosyltransferase and belongs to the fields of gene engineering and enzyme engineering. According to the present invention, a mutant having higher disproportionation activity of cyclodextrin glycosyltransferase is obtained by mutating the cyclodextrin glycosyltransferase. The disproportionation activity of enzymes of mutants V6D, S90G, T168A, T171A, T383A, G608A and V6D/S90G/T168A/T171A/T383A/G608A is respectively 1.89 times, 1.21 times, 1.21 times, 1.22 times, 1.32 times, 2.03 times and 3.16 times that of the wild enzyme in shake flask fermentations. The present invention has certain significance for the industrial production of cyclodextrin glycosyltransferase, and improves the application potential of the enzyme in food, medicine and chemical industries. | 2020-06-11 |
20200181586 | COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION - Described herein are oligosaccharyl transferases for use in N-glycosylating proteins of interest in vitro and in host cells. Methods for using such oligosaccharyl transferases, nucleic acids encoding such oligosaccharyl transferases, and host cells comprising such oligosaccharyl transferases are also provided herein. Glycoconjugates generated by using such oligosaccharyl transferases are also provided herein. | 2020-06-11 |
20200181587 | POLYMERASES, COMPOSITIONS, AND METHODS OF USE - Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain high fidelity under reduced incorporation times, as well as methods and kits using the same. | 2020-06-11 |
20200181588 | 2-O-Sulfation Enzyme Mutant and 3-O-Sulfation Enzyme Mutant, and Method for Using Same - The present invention provides a 2-OST mutant exhibiting a high activity. Specifically, the present invention provides a 2-O-sulfation enzyme mutant, having a substitution of a leucine residue at position 321 with a basic amino acid residue in any one amino acid sequence of: (a) the amino acid sequence of SEQ ID NO: 2; (b) an amino acid sequence comprising one or several amino acid substitutions, deletions, insertions, or additions in the amino acid sequence of SEQ ID NO: 2; (c) an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 2; (d) the amino acid sequence consisting of amino acid residues at positions 69 to 356 in the amino acid sequence of SEQ ID NO: 2; (e) an amino acid sequence comprising one or several amino acid substitutions, deletions, insertions, or additions in the amino acid sequence consisting of amino acid residues at positions 69 to 356 in the amino acid sequence of SEQ ID NO: 2; (f) an amino acid sequence having 90% or more identity to the amino acid sequence consisting of amino acid residues at positions 69 to 356 in the amino acid sequence of SEQ ID NO: 2; and having a 2-O-sulfate transfer activity. | 2020-06-11 |
20200181589 | COMPOSITIONS AND METHODS FOR STROKE PREVENTION IN PEDIATRIC SICKLE CELL ANEMIA PATIENTS - The present invention includes compositions and methods for treating stroke in sickle cell anemia (SCA) patients. In certain embodiments, the patient is administered certain ENPP1- or ENNP3-containing polypeptides, mutants, or mutant fragments thereof. | 2020-06-11 |
20200181590 | Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof - This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme. | 2020-06-11 |
20200181591 | COMPOSITIONS AND METHODS FOR SITE-DIRECTED DNA NICKING AND CLEAVING - Aspects of the disclosure related to compositions and methods for site-directed DNA nicking and/or cleaving, and use thereof in, for example, polynucleotide assembly. | 2020-06-11 |
20200181592 | ENGINEERED ENZYMES - The present disclosure provides engineered RNA-guided enzymes for editing live cells. | 2020-06-11 |
20200181593 | ALPHA-AMYLASE VARIANT WITH ALTERED PROPERTIES - The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered properties relative to the parent alpha-amylase. | 2020-06-11 |
20200181594 | ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) - Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need thereof. The disclosed variants of ACE2 may include polypeptide fragments of ACE2 having ACE2 activity for converting AngII(1-8) to Ang(1-7). Suitable subjects suitable for the disclosed methods of treatment may include subjects having or at risk for developing diabetic and non-diabetic chronic kidney disease, acute renal failure and its prevention, chronic kidney disease, severe hypertension, scleroderma and its skin, pulmonary, kidney and hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, and an acute stroke. | 2020-06-11 |
20200181595 | Bacillus Licheniformis Host Cell - The present invention relates to | 2020-06-11 |
20200181596 | GENE THERAPY SYSTEMS AND RELATED METHODS FOR TREATMENT OF HEARING LOSS - The present disclosure describes gene therapy systems, and related methods, useful for treating and/or preventing deafness caused by genetic mutation of the TMPRSS3 gene or the LOXHD1 gene. The compositions and methods disclosed herein use adeno-associated viral (AAV) vector gene delivery of TRMPSS3 or LOXHD1 into the inner ear to restore activity of the TMPRSS3 gene or the LOXHD1 gene, respectively, promote hair cell survival and restore hearing in patients suffering from hearing loss. As disclosed herein, the systems and methods may utilize a combination of gene therapy (e.g., molecular therapeutics) for hearing loss caused by a genetic mutation together with implantation of a cochlear implant. | 2020-06-11 |
20200181597 | Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities - The present disclosure relates to arginase albumin binding domain (ABD) fusion proteins and methods of preparation and use thereof. Also provided are methods involving arginine depletion for the treatment of obesity, metabolic disorders, and related complications and comorbidities. | 2020-06-11 |
20200181598 | ARTIFICIAL NON-RIBOSOMAL PEPTIDE SYNTHASES AND THEIR USE - The present invention pertains to a novel architecture of non-ribosomal peptide synthases (NRPS). The invention provides artificial NRPS wherein the naturally occurring terminal condensation or thioesterase-domain is replaced by internal condensation or dual condensation/epimerization domains. Moreover, the present invention enables the portability of terminal condensation domains to unrelated NRPS in respect of peptide release of linear peptides. The replacement results in a product independent release of the synthesized product and therefore enables the rational design of NRPS. The invention provides the new NRPS, nucleic acids encoding them, methods for artificial NRPS generation, and methods for producing non-ribosomal peptides. | 2020-06-11 |
20200181599 | Immobilized enzyme Pickering emulsion reaction system and application thereof - An immobilized enzyme Pickering emulsion reaction system and application thereof are provided, comprising immobilized enzymes with a mesoporous nanomaterial carrier, an oil phase and an aqueous phase for forming an emulsion, wherein the emulsion has a particle diameter of 10-80 μm, which uses a reaction raw material as the oil phase, uses a butler solution as the aqueous phase, and uses the immobilized enzymes with the mesoporous nanomaterial carrier as both the catalyst and the emulsifier. Compared with conventional emulsions with additional organic reagents or emulsifiers, catalytic activity and stability the Pickering emulsion enzymatic reaction system of the present invention have been significantly improved. Products are easy to separate and purify, easy to reuse, and easy to scale up. The present invention has wider application scope, which is more conducive to environmental protection. | 2020-06-11 |
20200181600 | METHOD FOR ENRICHING BIOMOLECULES AND FOR REMOVING THE BIOMOLECULES FROM A BIOLOGICAL SAMPLE - A method includes enriching biomolecules and removal of the biomolecules from a biological sample. In the presence of particles, an alginate solution and salts of divalent and/or polyvalent cations or an acid are added to a biological sample, and an alginate-gel-biomolecule-complex is formed on the particles. The complex is removed from the sample by separation of the particles, and from which subsequently the biomolecules or ingredients of the biomolecules are released. The biomolecules, which shall be enriched, include cell-free nucleic acids, viruses or subcellular microparticles. The method is improved and simplified. | 2020-06-11 |
20200181601 | OB-FOLD USED AS SCAFFOLD FOR ENGINEERING NEW SPECIFIC BINDERS - The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule. | 2020-06-11 |
20200181602 | ASSAY METHODS AND COMPOSITIONS FOR DETECTING CONTAMINATION OF NUCLEIC ACID IDENTIFIERS - The present invention relates to nucleic acid samples for massively parallel sequencing. More particularly, the present invention relates to assay methods, compositions and kits for detecting contamination of nucleic acid identifiers such as sample barcodes. | 2020-06-11 |
20200181603 | MICROARRAY SYNTHESIS AND ASSEMBLY OF GENE-LENGTH POLYNUCLEOTIDES - There is disclosed a process for in vitro synthesis and assembly of long, gene-length polynucleotides based upon assembly of multiple shorter oligonucleotides synthesized in situ on a microarray platform. Specifically, there is disclosed a process for in situ synthesis of oligonucleotide fragments on a solid phase microarray platform and subsequent, “on device” assembly of larger polynucleotides composed of a plurality of shorter oligonucleotide fragments. | 2020-06-11 |
20200181604 | PROTEIN ARRAYS AND METHODS OF USING AND MAKING THE SAME - Methods and devices are provided for preparing a protein array having a plurality of proteins. In one embodiment, the method includes providing a plurality of nucleic acids each having a predefined sequence and expressing in vitro a plurality of proteins from the plurality of nucleic acids. In another embodiment, protein arrays having a solid surface and a microvolume are also provided. The solid surface can have a plurality of anchor oligonucleotides capable of hybridizing with a plurality of nucleic acids. The microvolume can cover each of the plurality of anchor oligonucleotides and can be configured to produce a polypeptide from each of the plurality of nucleic acids. | 2020-06-11 |
20200181605 | HIGH-THROUGHPUT PROTEIN ANALYSIS METHOD AND SUITABLE LIBRARY THEREOF - A high-throughput protein analysis method includes: using a tagged semi-cloned mouse library to perform parallel indicator analysis on a plurality of different target proteins of interest with one or several tag protein antibodies. In the tagged semi-cloned mouse library, each semi-cloned mouse is a semi-cloned mouse obtained by culturing after injecting an androgenetic haploid embryonic stem cell into an ovum, or a sexually propagated progeny thereof, the androgenetic haploid embryonic stem cell contains a gene that expresses a fusion protein of a target protein of interest and a tag protein, and the semi-cloned mouse can express the fusion protein of the target protein of interest and the tag protein. The system is suitable for high-throughput in vivo, real-time and dynamic research for research on biomacromolecules. | 2020-06-11 |
20200181606 | A Method of Amplifying Single Cell Transcriptome - The present disclosure provides a method for amplifying RNA using a combination of reverse transcription and multiple annealing and looping based amplification cycles. Primers are used such that the resulting amplicons include a first cell specific barcode sequence, a second cell specific barcode sequence and a unique molecular identifier barcode sequence. | 2020-06-11 |
20200181607 | TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES - The present invention relates to tetramolecular parallel G-quadruplex-forming oligonucleotides. If G-quadruplexes are of prime importance in biology, their use is hampered by the propensity of G4-prone DNA molecules, in particular G4-prone DNA molecules of long size, to adopt many different G4 topological conformations or other alternative foldings. By introducing a lipid modification at the end of the oligonucleotide, the inventors succeeded in obtaining long tetramolecular parallel G-quadruplexes (tpG4). The present invention thus concerns an oligonucleotide modified by substitution at the 5′ or the 3′ end by a lipid moiety, wherein said oligonucleotide comprises a nucleic acid sequence of at least 10 nucleotides, said nucleic acid sequence including a series of at least 4 consecutive guanine residues located in the middle of said sequence. A tetramolecular parallel G-quadruplex comprising 4 identical modified oligonucleotides as defined above, wherein each of the 4 consecutive guanine residues included in the middle of the nucleic acid sequence of each oligonucleotide respectively form G-quartets with the corresponding guanine residues of the other 3 oligonucleotides, said G-quartets being stabilized by π-π staking and Hoogsteen hydrogen bonding, is also contemplated. The modified oligonucleotides have preferably the general formula (I) or (II), wherein the oligonucleotides are modified by substitution at the 5′ or the 3′ end by a lipid moiety, and said oligonucleotides comprise a nucleic acid sequence of at least 10 nucleotides, said nucleic acid sequence including a series of at least 4 consecutive guanine residues located in the middle of said sequence. | 2020-06-11 |
20200181608 | METHOD FOR KNOCKING OUT TARGET GENE IN T CELL IN VITRO AND crRNA USED IN THE METHOD - Provided is a method for knocking out target genes in T cells in vitro based on the CRISPR-Cas9 system. Also provided are crRNAs that target the TRAC, B2M and PD1 genes, and a kit comprising sgRNA formed by linking the crRNA and tracrRNA corresponding to a Cas9 protein, the Cas9 protein, an oligo deoxyribonucleic acid (N-oligo) or a milt DNA fragment. The kit is used to knock out the TCR, B2M and/or PD1 genes in T cells. Also provided are T cells with gene knockout, obtained according to a method of the present invention and uses thereof. | 2020-06-11 |
20200181609 | NEEDLE-BASED DEVICES AND METHODS FOR IN VIVO DIAGNOSTICS OF DISEASE CONDITIONS - Diagnostic devices and methods are provided for screening for a disease condition, include a cancer condition or a mendelian disease. Described herein are diagnostic devices for contacting cell-free nucleic acids or circulating tumor cells in vivo comprising a needle having a body and a detection reaction module attached to the body. | 2020-06-11 |
20200181610 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY - The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided. | 2020-06-11 |
20200181611 | NUCLEIC ACIDS COMPRISING IMPREFECT HAIRPINS - The present invention provides an RNA comprising in the 5′ to 3′ direction a first sequence and a second sequence, the first sequence being spaced apart from the second sequence by a spacer sequence, the first and second sequences being substantially complementary and forming a duplex via Watson and Crick base pairing, the second sequence being able to hybridise with the mRNA of a target gene in an organism, the RNA being substantially in the form of a hairpin, the second sequence being fully complementary to the said mRNA along the region at which it hybridises, the first sequence comprising nucleotide bases which do not Watson and Crick base pair with the corresponding bases in the second sequence of the duplex wherein the duplex does not comprise regions of 3 or more consecutive mismatched bases or an RNA comprising in the 5′ to 3′ direction a first sequence and a second sequence, the first sequence being spaced apart from the second sequence by a spacer sequence, the first and second sequences being substantially complementary and forming a duplex via Watson and Crick base pairing, the first sequence being able to hybridise with the mRNA of a target gene in an organism, the RNA being substantially in the form of a hairpin, the first sequence being fully complementary to the said mRNA along the region at which it hybridises, the second sequence comprising nucleotide bases which do not Watson and Crick base pair with the corresponding nucleotide bases in the first sequence of the duplex, wherein the duplex does not comprise regions of 3 or more consecutive mismatched bases. | 2020-06-11 |
20200181612 | METHOD OF TREATING CANCER BY ANTISENSE OLIGONUCLEOTIDES TARGETING PRDM15 - The present invention relates to antisense oligonucleotides for modulating the activity of PRDM15 and use thereof in the treatment of cancer. In particular, said antisense oligonucleotides are capable of inducing the skipping of an exon of a PRDM15 mRNA. The present invention also relates to a method for determining prognosis in a patient with cancer, or selecting a therapeutic strategy for a patient with cancer, by assessing the level of PRDM15 nucleic acid, protein or activity in a sample. | 2020-06-11 |
20200181613 | COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING - Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. | 2020-06-11 |
20200181614 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1. | 2020-06-11 |
20200181615 | ANTI-INFLAMMATORY TREATMENT VIA INHIBITION OF ENDOTHELIAL CELL KINESIN LIGHT CHAIN 1, VARIANT 1 (KLC1C) - Provided herein are compositions and methods for the inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C) expression and/or activity, and treatment or prevention of inflammation therewith. | 2020-06-11 |
20200181616 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE - The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration. | 2020-06-11 |
20200181617 | CHEMICALLY MODIFIED RNA APTAMERS AND USES THEREOF - Provided are chemically modified ribonucleic acid (RNA) aptamers comprising one or more of 2′F guanylate, 2′OMe cytidylate, 2′OMe adenylate, and a deoxy pyrimidine nucleotide with a moiety on the 5 position of the pyrimidine; and methods of making the aptamers. | 2020-06-11 |
20200181618 | FLUOROGEN-BINDING RNA APTAMERS - RNA aptamers are disclosed with distinct fluorescent properties, fluorophore binding affinities, and salt dependence. Also disclosed are corresponding fluorophores, with selected fluorophores evidencing high cellular permeability. The aptamer's high fluorophore affinities, the high brightness of the bound complexes, and their thermal and salt stability, provide distinct aspects of the disclosed aptamers. | 2020-06-11 |
20200181619 | APTAZYME-EMBEDDED GUIDE RNAS FOR USE WITH CRISPR-CAS9 IN GENOME EDITING AND TRANSCRIPTIONAL ACTIVATION - Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and/or improving the specificity of RNA-programmable proteins, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off” state, which control the binding and, in certain instances, cleavage activity of RNA-programmable proteins (e.g., RNA-programmable endonucleases). By incorporating ligand-responsive self-cleaving catalytic RNAs (aptazymes) into guide RNAs, a set of aptazyme-embedded guide RNAs was developed that enable small molecule-controlled nuclease-mediated genome editing and small molecule-controlled base editing, as well as small molecule-dependent transcriptional activation in mammalian cells. | 2020-06-11 |
20200181620 | INHIBITORS OF DEK PROTEIN AND RELATED METHODS - The present invention provides methods of treatment using inhibitors of DEK protein and DEK activity. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which DEK has been implicated. Such inhibitors of DEK protein include, but are not limited to, pharmaceutical compositions including single stranded DNA or RNA aptamers capable of binding to DEK. In some embodiments, such aptamers are useful for diagnosing DEK related diseases or conditions. Related kits and compositions are further provided. | 2020-06-11 |
20200181621 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE LNCRNA SAF TO DRIVE APOPTOTIC CELL DEATH IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED HUMAN MACROPHAGES - Provided are compositions and methods for prophylaxis or therapy for human immunodeficiency virus (HIV) infection. The compositions and methods involve use of RNAi agents targeted to an anti-apoptotic long non-coding RNA (lncRNA) that is IncRNA SAF (FAS-AS1) or HOXA-AS2. The RNAi agents preferentially induce apoptosis of HIV infected macrophages. RNAi agents, and macrophages containing the RNAi agents, are also provided. | 2020-06-11 |
20200181622 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field - The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis. | 2020-06-11 |
20200181623 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING - The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one cytidine deaminase protein or catalytic domain thereof. | 2020-06-11 |
20200181624 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS - Provided herein is a system for inducible expression of a chimeric antigen receptor in cells, such as mammalian cells. The system comprises: a) a first nucleic acid comprising a first promoter inducible by a drug, wherein the first nucleic acid is operably linked to a first polynucleotide that encodes a chimeric antigen receptor, which comprises a ligand binding domain that is specific for a ligand selected from the group consisting of a tumor specific molecule, a viral specific molecule, and any other selected molecule expressed on a target cell population, wherein the ligand elicits recognition, modulation, inhibition, and/or elimination by a lymphocyte, a second polynucleotide, which encodes a spacer or an optimized polypeptide spacer, a third polynucleotide, which encodes a transmembrane domain and a fourth polynucleotide, which encodes an intracellular signaling domain and b) a second nucleic acid comprising a second promoter that is operably linked to a nucleic acid encoding a transcriptional activator for the first promoter inducible by drug, wherein the system is inducible by an amount of the drug that is less than a comparable system utilizing a wild type HEA3 chimeric transcription factor, or the system has an enhanced transcriptional expression at a given concentration of the drug compared to a wild type HEA3. Methods of making such cells and methods of treatment using these cells are also provided. | 2020-06-11 |
20200181625 | METHODS AND COMPOSITIONS FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns re-combinant polypeptides and uses thereof | 2020-06-11 |
20200181626 | COMPOSITIONS OF SELF-REPORTING TRANSPOSON (SRT) CONSTRUCTS AND METHODS FOR MAPPING TRANSPOSON INSERTIONS - Among the various aspects of the present disclosure is the provision of compositions and methods for mapping transposon insertions. Applications can include mapping the locations of self-reporting transposons (SRTs) from thousands of single cells in parallel, while simultaneously measuring mRNA abundance from the same single cells; analyzing genome-associated protein (GAP) (e.g., transcription factor) binding/interactions in a small number of cells in bulk, without single cell resolution; lineage tracing; or as an improved readout for transposon mutagenesis screens. | 2020-06-11 |
20200181627 | PROMOTER FOR HETEROLOGOUS EXPRESSION - The present invention is directed to a nucleic acid construct comprising a polynucleotide operably linked to one or more control sequence that directs the expression of the polynucleotide in a host cell, wherein at least one control sequence comprises a promoter sequence of an operon comprising a secA gene or a functional fragment or functional variant thereof and wherein said promoter sequence is heterologous to the polynucleotide. In a further embodiment, the invention is directed to an expression vector and a host cell comprising the nucleic acid construct comprising the promoter sequence described herein and a method of expressing a polynucleotide in a host cell. | 2020-06-11 |
20200181628 | GENETIC CONTROL OF CELL SIZE - Described herein are mutant cyanobacterial cell populations that have a smaller mean cell length than wild type cyanobacterial cell populations of the same species. | 2020-06-11 |
20200181629 | YEAST EXPRESSING A SYNTHETIC CALVIN CYCLE - A yeast comprising a nucleotide sequence expression system expressing a synthetic Calvin cycle comprising heterologous genes, which include at least a) a gene encoding an enzyme from the class of the ribulose-bisphosphate carboxylases (EC number: 4.1.1.39) (RuBisCO gene); and b) a gene encoding an enzyme from the class of the ribulose phosphate kinases (EC number: 2.7.1.19) (PRK gene), which is expressing; wherein the yeast optionally comprises a heterologous expression construct expressing a gene of interest (GOI) and/or wherein each of said RuBisCO gene and said PRK gene, is fused with a nucleotide sequence encoding a peroxisomal targeting signal (PTS). | 2020-06-11 |
20200181630 | PLANT REGULATORY ELEMENTS AND METHODS OF USE THEREOF - The present disclosure provides compositions and methods for regulating expression of heterologous nucleotide sequences in a plant. Compositions include a novel nucleotide sequence for regulatory elements from Lamium Leaf Distortion Associated Virus. A method for expressing a heterologous nucleotide sequence in a plant using the regulatory element sequences disclosed herein is provided. The method comprises transforming a plant or plant cell with a nucleotide sequence operably linked to one of the regulatory elements of the present disclosure. | 2020-06-11 |
20200181631 | Plants and Methods for Increasing and Decreasing Synthesis of Cannabinoids - This disclosure relates to new plants and methods for increasing and decreasing synthesis of cannabinoids. The plants disclosed herein comprise unnatural ratios and concentrations of cannabinoids in plants of genus | 2020-06-11 |
20200181632 | METHODS FOR ENGINEERING PROANTHOCYANIDINS (PAS) IN PLANTS BY AFFECTING MYB TRANSCRIPTION FACTORS - The amount of proanthocyanidins (PAs) found in cells of plants can be engineered or adjusted through regulation of transcription factors that affect PA biosynthesis. Increasing expression of genes encoding TT2-type MYB transcription factors, including homologs of AtTT2 of | 2020-06-11 |
20200181633 | OLIGOMERIC VACCINES FROM PLANTS BY S-TAG-S-PROTEIN FUSIONS - The present invention relates to a method for production of an oligomeric protein in eukaryotic cells by co-expression of two fusion proteins in eukaryotic cells comprising a protein-S-Tag fusion protein, wherein the protein is an antigen or an antibody, and a S-protein-tail piece (tp) fusion protein. Furthermore the present invention relates to an oligomeric protein comprising at least a protein-S-Tag fusion protein and a S-protein-tail piece (tp) fusion protein, wherein the protein of the protein-S-Tag fusion protein is an antigen or an antibody, and the use in vaccines. | 2020-06-11 |
20200181634 | ENHANCEMENT OF PLANT YIELD VIGOR AND STRESS TOLERANCE - Altering the activity of specific regulatory proteins in plants, for example, by knocking down or knocking out HY5 clade or STH2 clade protein expression, or by modifying COP1 clade protein expression, can have beneficial effects on plant performance, including improved stress tolerance and yield. | 2020-06-11 |
20200181635 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING IMPROVED NITROGEN USE EFFICIENCY CHARACTERISTICS IN PLANTS - Methods and materials for modulating low-nitrogen tolerance levels in plants are disclosed. For example, nucleic acids encoding low nitrogen tolerance-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased low-nitrogen tolerance levels and plant products produced from plants having increased low-nitrogen tolerance levels. | 2020-06-11 |
20200181636 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODULATED GROWTH RATE AND BIOMASS IN PLANTS GROWN IN SALINE AND OXIDATIVE CONDITIONS - The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of improved plant size, vegetative growth, growth rate, seedling vigor and/or biomass in plants challenged with saline and/or oxidative stress conditions. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having plant size, vegetative growth, growth rate, seedling vigor and/or biomass that are improved in saline and/or oxidative stress conditions with respect to wild-type plants grown under similar conditions. | 2020-06-11 |
20200181637 | DROUGHT AND HEAT TOLERANCE IN PLANTS - Methods and materials for modulating heat and/or drought tolerance in plants are disclosed. For example, nucleic acids encoding heat and/or drought-tolerance polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased heat and/or drought tolerance and plant products produced from plants having increased heat and/or drought tolerance. | 2020-06-11 |
20200181638 | DROUGHT AND HEAT TOLERANCE IN PLANTS - Methods and materials for modulating heat and/or drought tolerance in plants are disclosed. For example, nucleic acids encoding heat and/or drought-tolerance polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased heat and/or drought tolerance and plant products produced from plants having increased heat and/or drought tolerance. | 2020-06-11 |
20200181639 | RNAI APPROACH FOR CROP PEST PROTECTION - Provided herein is the identification of insect RNAi target genes (IRTG) involved in gut microbial clearance and containment and examples of a novel biotechnology for devising pesticidal RNAi approaches. | 2020-06-11 |
20200181640 | Chromobacterium Subtsugae Genome - Disclosed herein is the nucleotide sequence of the | 2020-06-11 |
20200181641 | COMPOSITIONS AND METHODS FOR CONTOLLING PLANT PESTS - Novel insecticidal proteins isolated from | 2020-06-11 |
20200181642 | NANOPARTICLE-MEDIATED GENE DELIVERY, GENOMIC EDITING AND LIGAND-TARGETED MODIFICATION IN VARIOUS CELL POPULATIONS - An improved nanoparticle for transfecting cells is provided. The nanoparticle includes a core polyplex and a silica coating on the core polyplex and, optionally, a polymer attached to an outer surface of the silica coating, where the polyplex includes an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide. Also provided is an improved method of modifying intracellular polynucleotides. The method includes contacting a cell with a nanoparticle that includes a core polyplex and a silica coating on the core polyplex and, optionally, a polymer attached to an outer surface of the silica coating, where the polyplex includes an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide. | 2020-06-11 |
20200181643 | METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM - The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections. | 2020-06-11 |
20200181644 | SYNTHETIC COMBINATORIAL AAV3 CAPSID LIBRARY - Compositions and methods for producing modified AAV Cap genes and combinatorial libraries of chimeric AAV vectors and virions in an AAV serotype 3 background. Selecting for modified AAV3 virions displaying cell- or tissue-specific tropisms differing from WT AAV3. Using the synthetic combinatorial AAV3 capsid libraries for introducing into a selected target host cells one or more nucleic acid molecules useful in diagnostic and/or therapeutic gene-therapy regimens. | 2020-06-11 |
20200181645 | METHODS AND COMPOSITIONS FOR THE ACTIVATION OF TUMOR CYTOTOXICITY VIA HUMAN GAMMA-DELTA T-CELLS - The present disclosure relates generally to methods and compositions for activating gamma-delta (GD) T cells. Such methods and compositions can be used to treat cancer. | 2020-06-11 |
20200181646 | SELF-REGULATING AAV VECTORS FOR SAFE EXPRESSION OF MECP2 IN RETT SYNDROME - In some aspects, the disclosure relates to compositions and methods of engineering a transgene. In some embodiments, the disclosure provides self-regulating recombinant nucleic acids, viral vectors and pharmaceutical compositions comprising a MeCP2 transgene. In some embodiments, compositions and methods described by the disclosure are useful for treating diseases and disorders associated with a loss of function mutation, for example Rett syndrome. | 2020-06-11 |
20200181647 | BIOLOGICALLY ACTIVE SYNTHETIC NANOPARTICLE CONSTRUCTS AND METHODS OF USE THEREOF - This application discloses the compositions comprising biologically active synthetic nanoparticle constructs and methods of use thereof to modify gene expression including transcriptional activation and transcriptional repression. | 2020-06-11 |
20200181648 | METHODS AND COMPOSITIONS TO INCREASE HUMAN SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION, AND DERIVATION OF HUMAN NT-ESC - The present invention provides methods and compositions to improve the efficiency of somatic cell nuclear transfer (SCNT) of human cells and the consequent production of human nuclear transfer ESC (hNT-ESCs). More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of human donor somatic cells prevents efficient human somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of hSCNT by exogenous or overexpression of the demethylase KDM4 family and/or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases SUV39h1 and/or SUV39h2. | 2020-06-11 |
20200181649 | HYBRID FORMULATION OF RESPONSIVE POLYMERIC NANOCARRIERS FOR THERAPEUTIC AND DIAGNOSTIC DELIVERY - The present invention provides a nanocomplex comprising at least one agent and a nanocarrier. The agent is bound to the nanocarrier. The nanocarrier comprises at least one cationic polymer responsive to a stimulus, at least one anionic polymer and at least one lipid. The agent is capable of being released from the nanocarrier upon exposure to the stimulus. The released agent is active. The nanocomplex may be used to deliver the agent into cells, in which the agent may be released from the nanocarrier upon exposure of the cells to the stimulus. | 2020-06-11 |
20200181650 | PRIMARY CELL GENE EDITING - Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided. | 2020-06-11 |
20200181651 | REPAIRING COMPOUND HETEROZYGOUS RECESSIVE MUTATIONS BY ALLELE EXCHANGE - The disclosure in some aspects relates to methods and compositions for repairing mutations (e.g., compound heterozygous mutations) that are widely found in patients having certain diseases (e.g., monogenic recessive diseases). In some aspects, the disclosure provides a method for targeted allelic exchange using recombinant gene editing complex. | 2020-06-11 |
20200181652 | CONVERSION OF METHYLGLYOXAL INTO HYDROXYACETONE USING NOVEL ENZYMES AND APPLICATIONS THEREOF - The present invention relates to new methylglyoxal reductase (MGR) enzymes which are useful for efficiently converting methylglyoxal into hydroxyacetone. The invention more particularly relates to a method for efficiently converting methylglyoxal into hydroxyacetone using said enzymes, to a method for producing 1,2-propanediol using a microorganism overexpressing said enzymes, and to said microorganism. | 2020-06-11 |
20200181653 | PROCESS FOR PRODUCING AN ORGANIC COMPOUND - Described herein is a process of producing an organic compound, the process including: I) cultivating a genetically modified microorganism in a culture medium including sucrose as an assimilable carbon source to allow the genetically modified microorganism to produce the organic compound, and II) recovering the organic compound from the fermentation broth obtained in process step I) The genetically modified microorganism includes A) at least one genetic modification that leads to an increased activity of the enzyme encoded by the rbsK-gene, compared to the original microorganism that has not been genetically modified, and the original microorganism belongs to the family Pasteurellaceae. Also described herein are a genetically modified microorganism and the use thereof for the fermentative production of an organic compound from sucrose as an assimilable carbon source. | 2020-06-11 |
20200181654 | AGLYCONE PRODUCTION PROMOTER - A technique is provided for degrading a resveratrol glycoside, or degrading a resveratrol glycoside and an isoflavone glycoside, to promote the production of an aglycone(s), thereby enhancing the absorption thereof into a living body. A bacterium belonging to the genus | 2020-06-11 |
20200181655 | PROCESS FOR THE MANUFACTURE OF BUTANOL OR ACETONE - A process for the manufacture of butanol, acetone and/or other renewable chemicals is provided wherein the process utilises one or more of the group comprising by-products of the manufacture of malt whisky, such as draff, pot ale and/or spent lees, biomass substrates, such as paper, sludge from paper manufacture and spent grains from distillers and brewers, and diluents, such as water and spent liquid from other fermentations. The process comprises treating a substrate to hydrolyse it and fermenting the treated substrate at an initial pH in the range of 5.0 to 6.0. Also provided is a biofuel comprising butanol manufactured according to the process of the invention. | 2020-06-11 |
20200181656 | Industrial Fatty Acid Engineering General System for Modifying Fatty Acids - Compositions and methods for a hybrid biological and chemical process utilizing chemotrophic microorganisms that converts syngas and/or gaseous CO2 and/or a mixture of CO2 gas and H2 gas into one or more desaturated hydrocarbons, unsaturated fatty acids, hydroxy acids, or diacids. | 2020-06-11 |
20200181657 | HOST CELLS FOR DICARBOXYLIC ACID PRODUCTION - The present invention relates to a host cell which is capable of producing a dicarboxylic acid and which comprises at least one genetic modification in its genome resulting in the deficiency of at least one enzymatic step catalysing the oxidation of a cofactor. The invention also relates to a process for producing a dicarboxylic acid, which method comprises fermenting such a host cell in a suitable fermentation medium and producing the dicarboxylic acid. | 2020-06-11 |
20200181658 | IMPROVED MUCONIC ACID PRODUCTION FROM GENETICALLY ENGINEERED MICROORGANISMS - The subject of this invention is improvements in the yield and titer of biological production of muconic acid by fermentation. Increased activity of one or more enzymes involved in the muconic acid pathway leads to increased production of muconic acid. | 2020-06-11 |
20200181659 | HIGH PRODUCTIVITY METHANE FERMENTATION PROCESSES - Processes are provided for enhancing the productivity of fermenters during the metabolic conversion of methane-containing gases to products containing polyhydroxyalkanoate, which products can be used to make, for instance, animal feed or biodegradable, polymeric articles. The processes involve one or both of attenuating the heat generated to grow a population of microorganisms and removal of heat during the fermentation by removal of carbon dioxide. | 2020-06-11 |
20200181660 | CAROTENOID AND AMINO ACID BIOSYNTHESIS USING RECOMBINANT CORYNEBACTERIUM GLUTAMICUM - The present invention provides a method of producing astaxanthin and lysine in recombinant gram-positive bacteria comprising a nucleic acid sequence encoding for a crtZ-protein from | 2020-06-11 |
20200181661 | NOVEL POLYPEPTIDE AND METHOD FOR PRODUCING ORNITHINE-BASED PRODUCT USING THE SAME - The present disclosure relates to a novel polypeptide having an ability to export an ornithine-based product, and a method for producing an ornithine-based product using the same. | 2020-06-11 |
20200181662 | METHOD FOR THE HYDROLYSIS OF LIGNOCELLULOSIC BIOMASS - The present invention relates generally to the field of industrial biotechnology and particularly to an improved hydrolysis method for increasing sugar production from a high solids concentration of lignocellulosic biomass, especially one derived from Municipal Solid Waste (MSW) by enzymatic hydrolysis of a lignocellulosic biomass to obtain a slurry, wherein the hydrolysis comprises aliquot additions of enzyme and lignocellulosic biomass; and removal of sugars from the slurry and washing of the residual lignocellulosic biomass. | 2020-06-11 |
20200181663 | COMBINED USE OF AT LEAST ONE ENDOPROTEASE AND AT LEAST ONE EXO-PROTEASE IN AN SSF PROCESS FOR IMPROVING ETHANOL YIELD - The present invention relates to improved processes for producing ethanol from starch-containing materials by the combined use of at least one endo-protease and at least one exo-protease in an SSF process, and wherein the endo-protease is selected from a family M35 endo-protease and the exo-protease is selected from a family S53 exo-protease. More particularly the exo-protease should make up at least 5% (w/w) of the protease mixture. | 2020-06-11 |
20200181664 | METHODS AND SYSTEMS FOR CONVERSION OF BIOMASS MATERIALS INTO BIOFUELS AND BIOCHEMICALS - The present disclosure relates to methods and systems for converting biomass into biofuels and biochemicals. In particular, the present disclosure relates to methods and systems for converting biomass comprising lignocellulosic material into biofuels and biochemicals, such as those comprising fatty acid esters, that contribute to reduction of greenhouse gas emissions. | 2020-06-11 |